The promise for cell and gene therapies (CGTs) to revolutionize cancer therapy is immense, yet unlocking their full potential to treat more diseases and improve patient access will depend on […]
The field of cell and gene therapy (CGT) is undergoing a significant transformation, with a notable shift towards allogeneic platforms. Placing a spotlight on what has been deemed the ‘future […]
The possibility of allogeneic “off-the-shelf” engineered T cell therapies as an alternative to overcome the limitations of autologous therapies has long been a goal for the industry, with some of […]
The Human Leukocyte Antigens (HLA) are surface proteins on our cells and tissues serving as a mechanism for the body to distinguish between self and non-self, so our immune system […]
The simplicity and speed of immunomagnetic cell separation has made it the go-to method for isolating target cell populations since it was pioneered in 1990 by Miltenyi Biotec. The ability […]
Women’s History Month is celebrated every year in March to recognize and honor the contributions and achievements of women throughout history. The 2023 National Women’s History theme is “Celebrating Women […]
Is The Industry Prepared for Another Year of Rapid Growth? The cell and gene therapy (CGT) industry is expected to grow rapidly for the next 10 years with an increasing […]
The cell therapy market is valued at 15 billion dollars and is set to double in value by 2030. Cell therapy has been instrumental in the development of treatments like […]
In July of 2022, AllCells was acquired by Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists™. By combining over 30 years of cell and gene therapy (CGT) expertise, our […]
Unlike classical therapeutics (i.e., monoclonal antibodies), the raw starting materials for cell and gene therapies (CGTs) are derived from patient or donor cells. As such, these sources are not mass-produced […]
Copyright ©
AllCells. All rights reserved.
